2024 Q1 Form 10-Q Financial Statement

#000149315224020710 Filed on May 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $342.7K $413.2K
YoY Change -17.06% 25.82%
% of Gross Profit
Research & Development $2.195M $1.828M
YoY Change 20.06% 10.06%
% of Gross Profit
Depreciation & Amortization $900.00 $900.00
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.537M $2.241M
YoY Change 13.21% 12.66%
Operating Profit -$2.537M -$2.241M
YoY Change 13.21% 12.66%
Interest Expense $64.01K $116.2K
YoY Change -44.9% 493.36%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.473M -$2.125M
YoY Change 16.39% 7.88%
Income Tax
% Of Pretax Income
Net Earnings -$2.473M -$2.125M
YoY Change 16.39% 7.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.17
Diluted Earnings Per Share -$0.19 -$0.17
COMMON SHARES
Basic Shares Outstanding 12.86M shares 12.85M shares
Diluted Shares Outstanding 12.86M shares 12.85M shares

Balance Sheet

Concept 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.506M $11.91M
YoY Change -53.77% -39.67%
Cash & Equivalents $5.506M $11.91M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.506M $11.91M
YoY Change -53.77% -39.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.483K $8.099K
YoY Change -44.65% -30.84%
TOTAL ASSETS
Total Short-Term Assets $5.506M $11.91M
Total Long-Term Assets $4.483K $8.099K
Total Assets $5.510M $11.92M
YoY Change -53.77% -39.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $346.6K $220.9K
YoY Change 56.93% 0.0%
Accrued Expenses $43.03K $14.73K
YoY Change 192.12% -27.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $389.6K $235.6K
YoY Change 65.39% -2.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $389.6K $235.6K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $389.6K $235.6K
YoY Change 65.39% -2.32%
SHAREHOLDERS EQUITY
Retained Earnings -$52.84M -$43.60M
YoY Change 21.19%
Common Stock $57.96M $55.28M
YoY Change 4.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.121M $11.68M
YoY Change
Total Liabilities & Shareholders Equity $5.510M $11.92M
YoY Change -53.77% -39.66%

Cashflow Statement

Concept 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$2.473M -$2.125M
YoY Change 16.39% 7.88%
Depreciation, Depletion And Amortization $900.00 $900.00
YoY Change 0.0% 0.0%
Cash From Operating Activities -$1.783M -$1.557M
YoY Change 14.5% -20.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $299.1K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $299.1K
YoY Change
NET CHANGE
Cash From Operating Activities -$1.783M -$1.557M
Cash From Investing Activities
Cash From Financing Activities $299.1K
Net Change In Cash -$1.483M -$1.557M
YoY Change -4.71% -79.13%
FREE CASH FLOW
Cash From Operating Activities -$1.783M -$1.557M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2194513 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1827907 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
342688 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
413175 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
2537201 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2241082 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2537201 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2241082 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
64006 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
116180 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2473195 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12859685 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12859685 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12848165 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6700409 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6700409 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
299116 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2473195 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
5120852 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
5120852 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2473195 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2024Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
903 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
903 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
594522 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
594522 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
90265 usd
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
4940 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-27330 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1782565 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1556807 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
299116 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
299116 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1483449 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1556807 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6989424 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5505975 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11911219 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5505975 usd
CY2024Q1 us-gaap Payments For Rent
PaymentsForRent
2 usd
CY2024Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
the underlying lease expires in May of 2024
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2473195 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2124902 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2473195 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2124902 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12859685 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12859685 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2024Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
125737 usd
CY2023Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
35472 usd
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
220845 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
220845 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
893181 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
120 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2009657 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
15181 shares
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34157 usd
CY2023Q1 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2023Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
257269 usd
CY2024Q1 us-gaap Share Price
SharePrice
19.94
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1498128 shares
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.63
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
9512356 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.06 pure
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4221106 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5291250 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1843018 usd

Files In Submission

Name View Source Status
0001493152-24-020710-index-headers.html Edgar Link pending
0001493152-24-020710-index.html Edgar Link pending
0001493152-24-020710.txt Edgar Link pending
0001493152-24-020710-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
glsi-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glsi-20240331_cal.xml Edgar Link unprocessable
glsi-20240331_def.xml Edgar Link unprocessable
glsi-20240331_lab.xml Edgar Link unprocessable
glsi-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending